RAPPAPORT FAMILY INST FOR RES IN THE MEDICAL SCIENCES has a total of 14 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2008. It filed its patents most often in United States, EPO (European Patent Office) and Israel. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are GENEURO SA, SMITH VICTORIA and VALIRX PLC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 7 | |
#2 | EPO (European Patent Office) | 3 | |
#3 | Israel | 2 | |
#4 | WIPO (World Intellectual Property Organization) | 1 | |
#5 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Computer technology | |
#5 | Environmental technology |
# | Name | Total Patents |
---|---|---|
#1 | Karin Nathan | 5 |
#2 | Wildbaum Gizi | 5 |
#3 | Zohar Yaniv | 3 |
#4 | Anunu Rachel | 3 |
#5 | Neufeld Gera | 3 |
#6 | Netzer Nir | 3 |
#7 | Kessler Ofra | 3 |
#8 | Kigel Boaz | 2 |
#9 | Varshavsky Asya | 2 |
#10 | Barsheshet Yiftah | 2 |
Publication | Filing date | Title |
---|---|---|
US2016303196A1 | Use of CCL1 in therapy | |
US2016263182A1 | Compositions comprising semaphorins for the treatment of cancer and methods of selection thereof | |
US2017072019A1 | Compositions comprising il-31 and uses thereof | |
EP3027198A1 | Trophoblast derived microparticles for treating ischemic tissue and wounds | |
EP2781223A1 | Compositions comprising semaphorins for use in the treatment of cancer |